A Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity Against Ebola Virus

Protective Ebola virus (EBOV) antibodies have neutralizing activity and induction of antibody constant domain (Fc)-mediated innate immune effector functions. Efforts to enhance Fc effector functionality often focus on maximizing antibody-dependent cellular cytotoxicity, yet distinct combinations of functions could be critical for antibody-mediated protection. As neutralizing antibodies have been cloned from EBOV disease survivors, we sought to identify survivor Fc effector profiles to help guide Fc optimization strategies. Survivors developed a range of functional antibody responses, and we therefore applied a rapid, high-throughput Fc engineering platform to define the most protective profiles. We generated a library of Fc variants with identical antigen-binding fragments (Fabs) from an EBOV neutralizing antibody. Fc variants with antibody-mediated complement deposition and moderate natural killer (NK) cell activity demonstrated complete protective activity in a stringent in vivo mouse model. Our findings highlight the importance of specific effector functions in antibody-mediated protection, and the experimental platform presents a generalizable resource for identifying correlates of immunity to guide therapeutic antibody design.

[1]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[2]  Amalio Telenti,et al.  Structural and functional analysis of a potent sarbecovirus neutralizing antibody , 2020, bioRxiv.

[3]  L. Zeitlin,et al.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. , 2020, Cell host & microbe.

[4]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[5]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[6]  Pamela J. Glass,et al.  Differential requirements for FcγR engagement by protective antibodies against Ebola virus , 2019, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Gunn,et al.  Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses , 2019, The Journal of infectious diseases.

[8]  G. Alter,et al.  A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation , 2019, Journal of immunological methods.

[9]  G. Ferwerda,et al.  Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease , 2019, Front. Immunol..

[10]  Chuan Qin,et al.  Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. , 2019, JCI insight.

[11]  NK Cells Activated through Antibody-Dependent Cell Cytotoxicity and Armed with Degranulation/IFN-γ Production Suppress Antibody-dependent Enhancement of Dengue Viral Infection , 2019, Scientific Reports.

[12]  Dafna M. Abelson,et al.  A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. , 2019, Cell host & microbe.

[13]  J. Crowe,et al.  Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies. , 2018, The Journal of infectious diseases.

[14]  E. Saphire,et al.  Antibody-mediated protection against Ebola virus , 2018, Nature Immunology.

[15]  D. Lauffenburger,et al.  Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV , 2018, Nature Medicine.

[16]  J. Dye,et al.  Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection , 2018, Cell.

[17]  D. Lauffenburger,et al.  A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. , 2018, Cell host & microbe.

[18]  J. Crowe,et al.  Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein , 2018, Immunity.

[19]  D. Burton,et al.  Passive immunotherapy of viral infections: 'super-antibodies' enter the fray , 2018, Nature Reviews Immunology.

[20]  H. Howie,et al.  Affinity of human IgG subclasses to mouse Fc gamma receptors , 2017, mAbs.

[21]  Dafna M. Abelson,et al.  Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses , 2017, Cell.

[22]  J. Dye,et al.  Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability , 2017, Cell.

[23]  Daniel S. Chertow,et al.  The Pathogenesis of Ebola Virus Disease. , 2017, Annual review of pathology.

[24]  J. Taubenberger,et al.  IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.

[25]  Caitlin E. Mullarkey,et al.  Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus , 2016, Proceedings of the National Academy of Sciences.

[26]  J. Mascola,et al.  Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody , 2016, Science.

[27]  U. Baxa,et al.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies , 2016, Science.

[28]  D. Burton,et al.  Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak , 2016, Science.

[29]  James E. Crowe,et al.  Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection , 2016, Cell.

[30]  R. Baric,et al.  Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.

[31]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[32]  Fu-Tong Liu,et al.  Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.

[33]  Piet Gros,et al.  Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.

[34]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[35]  Lisa E. Gralinski,et al.  Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses , 2013, The Journal of infectious diseases.

[36]  Lisa Hensley,et al.  Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques , 2012, Proceedings of the National Academy of Sciences.

[37]  P. Parren,et al.  Crosstalk between Human IgG Isotypes and Murine Effector Cells , 2012, The Journal of Immunology.

[38]  P. Bruhns.  Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[39]  J. Ravetch,et al.  Mouse model recapitulating human Fcγ receptor structural and functional diversity , 2012, Proceedings of the National Academy of Sciences.

[40]  N. Bohorova,et al.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant , 2011, Proceedings of the National Academy of Sciences.

[41]  D. Burton,et al.  A Panel of IgG1 b12 Variants with Selectively Diminished or Enhanced Affinity for Fcγ Receptors To Define the Role of Effector Functions in Protection against HIV , 2011, Journal of Virology.

[42]  J. Peiris,et al.  Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.

[43]  Prida Malasit,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.

[44]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[45]  G. A. Lazar,et al.  Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.

[46]  J. Marvin,et al.  Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.

[47]  Louis M Weiner,et al.  Monoclonal antibodies for cancer immunotherapy , 2009, The Lancet.

[48]  Carola Engler,et al.  A One Pot, One Step, Precision Cloning Method with High Throughput Capability , 2008, PloS one.

[49]  G. A. Lazar,et al.  Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. , 2008, Molecular immunology.

[50]  J. Desjarlais,et al.  Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.

[51]  J. Stavenhagen,et al.  Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. , 2007, Cancer research.

[52]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[53]  A. Datta-Mannan,et al.  Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates , 2007, Drug Metabolism and Disposition.

[54]  R. Johnston,et al.  Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants , 2006, PLoS medicine.

[55]  M. Nonaka,et al.  Genomic view of the evolution of the complement system , 2006, Immunogenetics.

[56]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[57]  P. Bruhns,et al.  FcγRIV : A novel FcR with distinct IgG subclass specificity , 2005 .

[58]  H. Katinger,et al.  Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. , 2004, AIDS research and human retroviruses.

[59]  H. Young,et al.  Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection , 2004, The Journal of experimental medicine.

[60]  J. Tso,et al.  Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates* , 2004, Journal of Biological Chemistry.

[61]  S. Langermann,et al.  Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1 , 2002, The Journal of Immunology.

[62]  S. J. Hoffman,et al.  A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease , 2002, The Journal of experimental medicine.

[63]  D. Burton,et al.  Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody , 2002, Journal of Virology.

[64]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[65]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[66]  Leonard G. Presta,et al.  Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.

[67]  P. Parren,et al.  In vitro characterization of five humanized OKT3 effector function variant antibodies. , 2000, Cellular immunology.

[68]  D. Burton,et al.  Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection , 1999, Journal of Virology.

[69]  M. Bray,et al.  A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. , 1998, The Journal of infectious diseases.

[70]  P. Nickerson,et al.  Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. , 1995, Journal of immunology.